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Abstract
Background Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adju-
vant endocrine therapy after 2–3 years from tamoxifen to exemestane. This PathIES aimed to assess the role of immunohis-
tochemical (IHC)4 score in determining the relative sensitivity to either tamoxifen or sequential treatment with tamoxifen 
and exemestane.
Patients and methods Primary tumour samples were available for 1274 patients (27% of IES population). Only patients 
for whom the IHC4 score could be calculated (based on oestrogen receptor, progesterone receptor, HER2 and Ki67) were 
included in this analysis (N = 430 patients). The clinical score (C) was based on age, grade, tumour size and nodal status. 
The association of clinicopathological parameters, IHC4(+C) scores and treatment effect with time to distant recurrence-
free survival (TTDR) was assessed in univariable and multivariable Cox regression analyses. A modified clinical score 
(PathIEscore) (N = 350) was also estimated.
Results Our results confirm the prognostic importance of the original IHC4, alone and in conjunction with clinical scores, but 
no significant difference with treatment effects was observed. The combined IHC4 + Clinical PathIES score was prognostic 
for TTDR (P < 0.001) with a hazard ratio (HR) of 5.54 (95% CI 1.29–23.70) for a change from 1st quartile (Q1) to Q1–Q3 
and HR of 15.54 (95% CI 3.70–65.24) for a change from Q1 to Q4.
Conclusion In the PathIES population, the IHC4 score is useful in predicting long-term relapse in patients who remain 
disease-free after 2–3 years. This is a first trial to suggest the extending use of IHC4+C score for prognostic indication for 
patients who have switched endocrine therapies at 2–3 years and who remain disease-free after 2–3 years.
Keywords Breast cancer · Aromatase · Prognosis
Introduction
The use of aromatase inhibitors (AIs) within the adjuvant 
setting, either upfront or sequentially before or after tamox-
ifen, has now been established given the results of several 
international studies [1–7]. Recently Goss et al. reported 
results of MA.17R that there was a reduction in contralat-
eral breast cancers and increased disease-free survival, even 
though there was no overall survival benefit, supporting the 
extended use of an AI as adjuvant endocrine therapy for 
10 years [8]. However, there is still considerable uncertainty 
as to whether such treatment is necessary for all patients 
and whether some patients can be treated solely with 
either tamoxifen or AI alone or switched to AI following 
tamoxifen treatment such as was done in the IES trial [3]. 
The IES (Intergroup Exemestane Study) trial continues to 
report, even in its final analysis, at a median follow-up time 
of 12 years, a modest improvement in overall survival for 
those who ‘switched’ treatments (in preparation).
Whilst women with hormone receptor positive breast 
cancer can acquire resistance to endocrine treatment, it cur-
rently remains uncertain how this resistance occurs, and 
whether different mechanisms of resistance between the 
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two treatment types exist. Several gene expression assays 
have been developed with the aim of distinguishing those 
patients who will relapse early on adjuvant endocrine ther-
apy, including the  Prosigna®, Oncotype  DX®,  EndoPredict® 
and Breast cancer Index™ but, as yet, none have been evalu-
ated for their capacity to distinguish benefit from different 
forms of endocrine therapy.
We had established a translational group (PathIES) as 
part of the IES trial to evaluate the potential role of vari-
ous candidate biomarkers to distinguish the effectiveness 
of tamoxifen and AI. This group has already reported the 
results of ERβ variants and its possible role in helping to 
predict appropriate endocrine therapy for patients in IES [9].
The immunohistochemical (IHC) 4 + Clinical (C) score is 
a prognostic tool based on quantitative assessment of immu-
nohistochemical biomarkers (ER, Progesterone receptor 
(PgR), HER2 and Ki67) and the clinicopathologic variables 
(tumour grade, size, nodal status, tumour grade, treatment 
with AI or tamoxifen) [10–12]. The IHC4+C was developed 
to predict the residual risk of distant recurrence at 9 years in 
postmenopausal women with ER positive tumours treated 
with 5 years of adjuvant endocrine therapy only (i.e. no 
chemotherapy) [13, 14]. However, to date, there is no report 
to evaluate the prognostic value of IHC4+C to patients who 
have received adjuvant tamoxifen for 2–3 years, followed 
by subsequent exemestane treatment to complete a total of 
5 years endocrine therapy.
We consider it important to examine the role of the IHC4 
score in predicting prognosis in patients who are switched 
from tamoxifen to an AI since this would provide a different 
cohort from other studies given that we include only those 
who remain disease-free at 2–3 years. This cohort therefore 
excludes patients who relapse early but more closely resem-
bles the cohort in whom continuation of therapy beyond 
5 years will increasingly be considered. We also report 
here on the role of IHC4 score in determining the relative 
sensitivity to either tamoxifen or sequential treatment with 
tamoxifen and exemestane.
Patients and methods
Study design
IES was a multicentre, international, randomised, double-
blind phase III study comparing exemestane 25 mg/day to 
tamoxifen 20 mg/day (30 mg in Denmark) for 2–3 years in 
postmenopausal women with ER+/unknown primary breast 
cancer who remained disease-free after receiving adjuvant 
tamoxifen therapy for 2–3 years. The study recruited 4724 
postmenopausal women from 37 countries (366 centres) 
between 1998 and 2003 and has shown a survival benefit 
for those with ER+/unknown cancers from switching to 
exemestane after 2–3 years tamoxifen [15, 16]. PathIES 
is a retrospective translational study that aims to identify 
markers predictive of response or resistance to tamoxifen 
or an AI. Pathological samples from the primary surgery (at 
least 2 years before randomisation into the main IES trial i.e. 
between 1996 and 2001) were collected retrospectively from 
1274 women enrolled in the IES (27% of IES patients). This 
article presents results from the analysis of IHC4 (ER, PgR, 
HER2 and Ki67) and IHC+C (IHC4 + clinical score based 
on nodal status, pathological tumour size, grade and age) on 
PathIES participants. Only PathIES participants for whom 
IHC4 could be calculated were included in this analysis. All 
clinical data used in the analyses were based on the snapshot 
taken for the most recent IES publication (median follow-up 
time was 91 months) [16] and the REMARK [17] criteria 
were employed for data reporting.
Patients
Patients were eligible for enrolment in the IES study if they 
had histologically confirmed, completely resected unilat-
eral invasive breast carcinoma positive for ERα or that was 
of unknown receptor status. Patients were postmenopausal 
and had received adjuvant tamoxifen therapy for at least two 
years but no more than three years and one month. The study 
design, detailed eligibility criteria and treatment schedules 
have been previously described [3]. Formalin-fixed paraf-
fin-embedded (FFPE) tumour samples were retrospectively 
collected in accordance with institutional guidelines, ethics 
requirements and national laws. Laws and regulations at the 
time of tissue collection on consent requirements, collection 
of archived FFPE samples from patients that were deceased 
and international sample transfers limited the number of 
countries that could participate in PathIES.
Immunohistochemistry
FFPE tissue blocks were received at the central labora-
tory, and tissue microarrays (TMAs) were constructed as 
described [9], except where lesions were of insufficient size. 
Pathology laboratories that were unable to submit FFPE 
tumour blocks were requested to provide 4–5 micron whole 
sections. Full information on immunohistochemistry was 
previously described [9].
Statistical analyses
The primary endpoint for this study was time to distant 
recurrence (TTDR) defined as time from random assign-
ment to treatments to distant recurrence, death from breast 
cancer or unknown cause without prior recurrence. The clin-
icopathological characteristics of patients selected for this 
171Breast Cancer Research and Treatment (2018) 168:169–178 
1 3
analysis to those not selected (due to unavailable tissue for 
the analysis, or unavailable markers for IHC4 assessment) 
were tabulated. No allowance has been made for multiple 
testing.
Calculation of IHC4 score and evaluation of its 
prognostic value among PathIES participants
Analysis was limited to ER+ PathIES patients as assessed 
centrally by either ≥ 1% positive stained cells or H-score ≥ 1 
or Allred ≥ 3. The Cuzick et al. [10] algorithm was adopted 
as follows, to derive the IHC4 score, which in combination 
with a clinical score (nodes, grade, age, tumour size) was 
tested for its prognostic value on our data.
 
In brief, the ER [10] was equivalent to ER H-score divided 
by 30 and PgR [10] equivalent to PR percentage of posi-
tive tumour nuclei cells divided by 10. The range of ER10 
and PgR would be 0–10. HER2 was considered positive if 
IHC staining was 3+ and negative for IHC 0, 1+, 2+. Ki67 
score was transformed as ln(1 + (4 × ki67)). The IHC4 risk 
groups were categorised as follows: quartile (Q) 1: < 25%, 
Q2–Q3: ≥ 25% and < 75%, Q4: ≥ 75%).
For the clinical score, Nj, Tj, Grj and  Agej denote cat-
egories of nodal status (N0, 1–3 N+ , > 3 N+), tumour 
size (< 1 cm (T0), 1–2 cm (T1–2), 2–3 cm (T2–3) and > 3 cm 
(T >3)), grade (I, II, III) and age (< 65, ≥ 65).
The anastrozole versus tamoxifen effect term was deemed 
inappropriate for the exemestane effect on the PathIES data 
to validate the prognostic model of IHC4+C and therefore it 
was omitted. The IHC4+C risk groups were also categorised 
based on the quartiles (Q) (Q1: < 25% vs Q2–Q3: ≥ 25% 
and < 75% vs. Q4: ≥ 75%).
Kaplan–Meier plots, log-rank tests and Cox proportional 
hazards models, as appropriate, were used to compare how 
time to distant recurrence varied according to the IHC4 and 
IHC4+C risk groups. The significance of treatment effect 
with risk groups was determined by an interaction test in the 
multivariable Cox model.
A calibration plot comparing the predicted and observed 
probability of distant relapse by 10 years assessed the per-
formance of the IHC4+C prognostic score. Patients were 
divided into ten groups according to their 10th percentiles 
of IHC4+C score; mean predicted values within each group 
IHC4 = 94.7x [−0.1 ER10 − 0.079 PgR10
+ 0.586 HER2 + 0.240x ln(1 + 4 x ki67) ]
Clinical score=100x [0.417 N1−3 + 1.566 N > 3
+ 0.93 x (0.497 T1−2 + 0.882 T2−3
+ 1.838 T > 3 + 0.559 Gr2 + 0.970 Gr3
+ 0.130 Age > 65]
.
were compared to the observed Kaplan–Meier estimates 
obtained for each group at 10 years.
Adjusting the prognostic clinical score model using 
PathIES parameters
To retain the comparability with the original IHC4+C 
model as reported by Cuzick et al., we used the same crite-
ria to categorise the following variables: age, nodal status, 
tumour size and grade. The association of clinicopathologi-
cal parameters, IHC4 score (included as continuous vari-
able) and the PathIES treatment effect (tam→exem vs. tam 
alone) with survival data was assessed in a univariable Cox 
regression analysis. For the multivariable Cox regression 
analysis, we applied a stepwise backward strategy to select 
the most prognostic factors, whilst forcing the selection to 
keep treatment in the model, as assessed by a significance 
level of 10% if not lower.
Results
Characteristics of PathIES participants
Of the 4724 postmenopausal women with ER+/unknown 
primary breast cancer included in the IES trial, 1483 from 89 
centres were recruited into PathIES study. Of those, material 
was available for 1274 women, 27% of the IES population or 
86% of the population recruited from centres participating 
in PathIES (Supplementary Table 1).
IHC4 scores
Of the 1274 cases, 800 were confirmed as ER+ by central-
ised review (Fig. 1). Interpretable immunohistochemical 
data for IHC4 markers were only available for 430 women 
of whom 350 had complete set of data for all clinical factors 
used in the analysis. In these 350 patients, there were 105 
recurrences of which 67 were distant recurrences. Table 1 
outlines the characteristics of those patients with avail-
able data on all IHC4 markers (N = 430) and those without 
(N = 4294) within IES population.
Part A: performance of IHC4 and IHC4+C on PathIES
Of 430 ER+ patients, 393 (91%) were PgR+, 186 (43%) 
expressed high proliferation (Ki67 ≥ 13%) and 20 (4.7%) 
were HER2+. The median IHC4 score on PathIES data 
was − 19.2 (IQR − 51.5, 10.2) whilst in the ATAC pop-
ulation this was − 4.2 (IQR − 29.9, 29.9). The HR for a 
change from the 1st quartile (Q1) to the Q2–Q3 was 1.45 
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(95% CI 0.73–2.88) and from Q1 to Q4 it was 2.32 (95% CI 
1.13–4.73) (P = 0.04, Fig. 2a; Table 2). Within treatment 
group, and possibly due to the low number of events and lack 
of power, IHC4 was no longer prognostic. No interaction 
was detected between IHC4 and treatment group (interac-
tion P = 0.96). The addition of the clinical score to the IHC4 
score resulted in more profound effects in separating patients 
associated with differential risks (Fig. 2b; Table 2).
Predicted probabilities of distant relapse at 10-year using 
IHC4+C (minus the treatment effect) were calculated. Fifty 
per cent of patients had predicted risk of relapse ≤ 10%, 
with 25% of patients with predicted risk of relapse over 
20%. When comparing the observed and predicted prob-
abilities of distant relapse at 10-year using IHC4+C (minus 
the treatment effect), the agreement between observed and 
predicted probabilities was good as shown by the calibration 
plot (Fig. 2c), though there is higher variability in patients 
with predicted risk of relapse > 10%.
Part B: adjusting the clinical model using PathIES 
parameters
PathIES patients had received adjuvant tamoxifen therapy 
for at least 2–3 years before trial entry therefore it was of 
particular interest to ascertain which clinical variables 
remain prognostic after this time interval. Nodal status, 
tumour size and IHC4 demonstrated a highly significant 
prognostic value when associated univariately with time 
to distant recurrence (Table 3). Such association remained 
in the multivariable model after backwards selection. The 
modified PathIES prognostic score was calculated as
IES
PathIES
Not recruited to PathIES 
(n = 3241) 
Centralised confirmed 
ER+ (n = 800)
Patients with IHC4 
scores (n = 430) 
With PR data
(n = 667) 
With HER2 data
(n = 584) 
No PR score
(n = 133) 
Unknown HER2
status (n = 216)
With Ki67 data
(n = 639) 
Unknown Ki67
status (n = 161)
FFPE received for 
PathIES (n = 1274) 
Eligible to PathIES 
(n = 1483) 
Patients in IES 
(n = 4724) 
FFPE not received for 
PathIES (n = 209)
Drop out of tissue cores / not enough 
tumour cells present (n = 234)
Patients switched 
to exemestane
(n = 222)
Patients continued
tamoxifen 
(n = 208)
Fig. 1  Consort diagram
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IHC4 + Clinical PathIES score = 100x (−0.13x exe+
0.46N
1- 3
+ 1.45N >
3
+1.37 T
1−2 + 1.65 T1−2 + 2.21 T >3
+0.0048 IHC4), where Nj and Tj denote categories of nodal 
status (N0, 1–3 N+, > 3 N+) and tumour size (T0, T1–2, T2–3, 
T  >3) as described above for the IHC4+C score, respectively. 
For ease of interpretation, the score has been multiplied by 
100. After computing this score for all patients, and catego-
rised into three groups with cutoffs 25% and 75%, Fig. 3a 
shows Kaplan–Meier curves for these groups according to 
the IHC4 + Clinical PathIES score.
The combined IHC4 + Clinical PathIES score was highly 
prognostic for outcome (P < 0.001): HR 5.54, 95% CI 
(1.29–23.70) for a change from Q1 to Q2–Q3 and HR 15.54, 
95% CI (3.70–65.24) for a change from Q1 to Q4 (added to 
Table 2 for comparison). Figure 3b shows the relationship of 
the combined IHC4 + Clinical PathIES score with the risk 
of distant recurrence after 9 years according to nodal status.
Discussion
To our knowledge, this is the first time that the IHC4 and 
IHC4 + Clinical score has been tested for its ability to pre-
dict relapse in a cohort of patients who switched to an AI at 
2–3 years, thus excluding those who relapsed early and more 
closely resembling the cohort who would potentially be con-
sidered for extended adjuvant therapy beyond 5 years. We 
found that patients with a IHC4 + Clinical score of ≥ 75th 
percentile have an approximately 50% risk of recurrence by 
10 years after switching at 2–3 years. This may imply that 
this subgroup should continue adjuvant endocrine therapy 
beyond the total of 5 years.
Prediction of late relapse is a matter of considerable con-
cern for patients who have switched therapies at 2–3 years 
and who remain disease-free after 2–3 years, since the 
current and planned randomised studies are insufficiently 
mature to assist their decision-making at the current time.
The IHC4 score has been confirmed as being predictive 
of early relapse by a number of groups, and is known to be 
especially valuable when combined with clinical prognos-
tic scores [10]. Recently it has been compared with other 
scoring systems for its ability to predict both early and late 
recurrences [18, 19]; although the PAM50 risk of recurrence 
(ROR) score was superior in this study, the IHC4 has been 
found to be an important scoring system.
Our results confirm the prognostic importance of IHC4, 
alone and in conjunction with clinical scores. Although 
results from the calibration plot indicated that the predic-
tion based on the published IHC4+C derived from TransA-
TAC study was higher than the actual observed probability 
in some groups of predicted risk > 10%, One possible reason 
for this is that PathIES patients were treated with tamoxifen 
for 2–3 years, and remained recurrence-free before being 
randomised. Our results, nevertheless, demonstrated the 
prognostic value of IHC4 to segregate patients associated 
with differential risks of recurrence. The predictive value 
of the calculator might be improved by adjusting the weight 
estimates for each of the factors, given this is a different pop-
ulation and potential prognostic time dependency of some of 
the clinical pathological variables. Additional study using an 
independent cohort of patients is needed to investigate the 
robustness of the estimates.
Table 1  Comparison of patient characteristics according to data avail-
ability (N = 430 v 4294)
Available IHC-4 markers
Yes (N = 430) No (N = 4294)
N % N %
Treatment
 Tamoxifen 208 48.4 2164 50.4
 Exemestane 222 51.6 2130 49.6
Age (years)
 < 60 142 33.0 1381 32.2
 60–69 191 44.4 1830 42.6
 70 + 97 22.6 1083 25.2
Grade
 GI 97 22.6 692 16.1
 GII 209 48.6 1778 41.4
 GIII 78 18.1 845 19.7
 Not assessable 2 0.5 101 2.4
 Unknown 44 10.2 878 20.4
Nodes
 Negative 193 44.9 2254 52.5
 1–3 N+ 143 33.3 1288 30.0
 >3 N+ 59 13.7 599 13.9
 Unavailable 35 8.1 153 3.6
Tumour size (cm)
 ≤ 2 246 57.2 2539 59.1
 >2 & ≤ 5 168 39.1 1548 36.1
 >5 13 3.0 109 2.5
 Unavailable 3 0.7 98 2.3
Histology type
 Infiltrating ductal 329 76.5 3278 76.3
 Infiltrating lobular 53 12.3 609 14.2
 Other 48 11.2 398 9.3
 Unavailable 0 0 9 0.2
Previous chemotherapy use
 Yes 76 17.7 1466 34.1
 No 354 82.3 2828 65.9
HRT use
 Yes 145 33.7 979 22.8
 No 276 64.2 3211 74.8
 Unavailable 9 2.1 104 2.4
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Several other scoring systems have been advocated for 
their ability to predict late recurrence in patients with ER 
positive breast cancer. Sestak et al. [19] compared IHC4, 
recurrence score (RS) as well as the PAM50 ROR score 
in patients enrolled in the ATAC study: here, node status, 
tumour size and the ROR score, a gene expression profile 
test, were the factors best able to predict long-term relapse. 
More recently, the TransATAC group compared the breast 
cancer index (BCI) (both linear and cubic) the OncotypeDX, 
as well as the IHC4 score; here the BCI (linear) had the 
best predictive value [20]. The components of this score 
that were most important were HOXB13/IL17BR. The rea-
son for these two factors being so important appears to be 
that HOXB3 can over-ride the tumour suppressor p21 whilst 
IL17 is now known to be the prime neutrophil-dependent 
growth promoter in breast cancer [21]. The importance of 
this ratio was also underscored by the reports on retrospec-
tive analysis of the ratio in the MA17 study and predicted 
those who may benefit from extended letrozole therapy 
[22]. Recently, TransATAC group reported that EndoPredict 
(EPclin), an alternative test combining an eight-gene signa-
ture (EP score) with tumour size and nodal status, provided 
more prognostic information than the OncotypeDX score for 
estimating late recurrence [23], which may partly due to the 
reason that the test includes the significant clinicopathologi-
cal variables.
Previously, an assessment of the predictive effects, in 
terms of therapy, of Ki67 had been reported by Viale 
et al. [24]. This report suggested that high Ki67 levels 
predicted benefit from aromatase inhibition. However, 
this result was not amalgamated with the other three com-
ponents of the IHC4 score, namely ER, PR and HER-2. 
In the current study, there were too few patients to enable 
an assessment of the IHC4 score for its capacity to pre-
dict which patients benefit from tamoxifen or exemestane 
after 2–3 years.
Recently, we carried out immunohistochemical staining 
for ER beta 1 and 2 in a subset of patients. Here, we found 
that, for those patients whose tumours expressed ER beta 
1, the beneficial effect of simply continuing tamoxifen was 
similar to the patients who switched treatment to exemes-
tane. Although requiring confirmation, this study suggests 
that it may be possible to ‘tailor’ treatment according to 
the primary tumour characteristics. This, combined with the 
IHC4 + clinical score, should enable us to optimise the type 
and duration of endocrine therapy.
Logrank test p-value: 0.04 Number of events / Total:
Q1 : 11 / 107 
Q2-Q3 : 32 / 215 
Q4 : 24 / 108 
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Fig. 2  a Time to distant recurrence according to quartiles (Q) 
of IHC4 score (Q1:  <  25% vs. Q2–Q3:  ≥  25% and  <  75% vs. 
Q4:  ≥  75%) (N  =  430) b Time to distant recurrence according to 
quartiles (Q) of the combined IHC4 + Clinical score (Q1: < 25% vs. 
Q2–Q3: ≥ 25% and < 75% vs. Q4: ≥ 75%) (N = 350). Of note, the 
clinical score did not include the treatment component. c Calibration 
plot of predicted versus observed probability of distant recurrence 
by 10  years for each 10th percentile of the IHC4  +  Clinical score 
(N = 350). DR distant recurrence. (NB: Perfect predictions should be 
on the 45°line.)
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There are a few caveats before translating these results 
into clinical practice; firstly, these patients did not receive 
trastuzumab; the study was initiated before the studies of 
adjuvant trastuzumab were mature and adjuvant trastu-
zumab became standard practice for patients whose tumours 
expressed HER-2; however, only 5% of patients had HER2 
over-expressed tumours in this study. Secondly, Ki67 meas-
urement, despite being the subject of a recent consortium 
statement remains a challenging analyte in tissue sections, 
due principally to heterogeneity of expression [25, 26]. Thus, 
all the Ki67 values were analysed and assessed in one central 
laboratory. Secondly, a large proportion of patients received 
chemotherapy in this study, and especially this substudy, and 
caution should be exercised in translating these results to 
patients who did not receive cytotoxic chemotherapy.
Finally, although tissue markers reflect the biology of 
breast cancers in large series such as this, they do not enable 
clinicians to accurately predict the type and duration of treat-
ment for individual patients; this is reflected by our find-
ing here that approximately 50% of those with the highest 
quartile of the IHC4 + clinical score have not yet relapsed.
Other methods of predicting effectiveness and dura-
tion of treatment include the assessment of cell-free DNA. 
Using sensitive detection methods it is possible to detect 
Table 2  Hazard ratio of IHC4 
and IHC4 + Clinical score and 
IHC4 + Clinical PathIES score
*Unlike the Cuzick estimates these omit any treatment effect from exemestane
HR hazard ratio, CI confidence interval
Data IHC4 score (N = 430) 
HR (95% CI)
IHC4 + Clinical score (N = 
350) HR (95% CI)
IHC4 + Clinical PathIES 
score (N = 350) HR (95% 
CI)
PathIES
 <25% 1.00 1.00 1.00
 25%- 1.45 (0.73–2.88) 3.80* (1.14–12.69) 5.54 (1.29–23.70)
 75%- 2.32 (1.13–4.73) 8.96* (2.70–29.67) 15.54 (3.70–65.24)
Table 3  Prognostic value 
of the IHC4 score and 
clinicopathological clinical 
factors as assessed in univariate 
and multivariable analysis
a The IHC4 score was calculated using the Cuzick et al. algorithm and comprised ER, PR, HER2 and Ki67
b The multivariable model was adjusted for treatment group and was selected using a stepwise backward 
selection at the 10% level
Univariate Multivariableb (N = 350)
N HR 95% CI (HR) P HR 95% CI (HR) P
Age (year) (N = 430)
 < 65 257 1.00
 ≥ 65 173 1.37 0.85–2.21 0.20
Nodes (N = 395)
 Negative 193 1.00 < 0.001 1.00 <0.001
 1–3 N+ 143 1.92 1.02–3.64 1.59 0.79–3.20
 >3 N+ 59 6.13 3.29–11.43 4.24 2.11–8.55
Tumour size (cm) (N = 427)
 ≤ 1 52 1.00 < 0.001
 >1– ≤ 2 194 1.90 0.56–6.38 3.93 0.52–29.55 0.03
 >2– ≤3 127 3.63 1.09–12.05 5.23 0.69–39.53
 >3 54 6.47 1.91–21.88 9.11 1.19–69.91
Tumour grade (N = 384)
 GI 97 1.00 0.46
 GII 209 1.31 0.64–2.68
 GIII 78 1.68 0.74–3.84
IHC4a (N = 430) 430 1.01 1.00–1.01 0.03 1.00 1.00–1.01 0.07
Treatment (N = 430)
 Tamoxifen 208 1.00 1.00 
 Exemestane 222 0.95 0.59–1.53 0.83 0.87 0.50–1.53 0.64b
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circulating DNA from apoptosis residual breast cancer cells. 
It has now been shown that copy number variation [27] and 
detection of mutations [28] potentially can predict which 
patients are resistant to therapy.
In summary, the IHC4 score is useful in predicting 
long-term relapse in patients who remain disease-free after 
2–3 years. Future, prospective studies are needed to define 
the role of IHC4 in selecting patients for long-term therapy.
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